Notes Regarding Gene Therapy
Product Candidates, Forward-Looking
Statements and Web Site Usage
Note Regarding Gene Therapy
Cardium Therapeutics and its affiliates are developing gene therapies for the potential treatment of cardiovascular and other diseases. To date, no gene therapy products have been approved for sale or use in humans in the U.S. Product candidates need to complete testing in human clinical trials to provide a basis for the U.S. Food and Drug Administration (FDA) or other health regulatory agency to review and potentially approve them for use in humans. The outcome of each stage of these clinical trials is necessarily uncertain as to the actual and perceived safety and efficacy of each potential treatment and the FDA would have to review and approve a licensing application before a product candidate could be marketed for any indication. Success in preclinical and early clinical trials does not ensure that later-stage or larger-scale clinical trials would be successful. Nor can there be any assurance that a product would ultimately prove to be safe and effective in humans or, even if approved, that it would compete favorably with other products. Please see the "Note Regarding Forward-Looking Statements" in this Web site for additional information regarding these and other risks and uncertainties.
Note Regarding Forward-Looking
Certain statements in this web site and related sites that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Cardium's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Cardium does not undertake any obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Cardium is a company with product candidates in various stages of ongoing development. As a result, a substantial number of statements contained in this Web site, including without limitation statements containing words such as "believes," "anticipates," "expects," "predicts," "plans," "intends," "could," "would," and "will," and words of similar import, may constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cardium, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For example, risks and uncertainties that exist in the company's operations and business environment include, without limitation, the company's early stage of product development and the limited experience in the development of gene therapies in general, its dependence upon proprietary technology, its current competition, its history of operating losses and accumulated deficits, its reliance on collaborative relationships, as well as uncertainties related to clinical trials including the actual or perceived safety or efficacy of a product candidate and the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks and uncertainties. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Cardium disclaims any obligation to update such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.